MSCs are a class of multipotent cells that are readily found in umbilical cord tissue, adipose tissue, bone marrow, dental pulp, and periosteum (a type of connective tissue that envelops bone). These cells are often called by other names as well, such as Medicinal Signaling Cells, Mesenchymal Stromal Cells, Marrow Stromal Cells, and Mesenchymal Stem Cells, despite much controversy in the field about using this term. [Read more…]
History of Cord Blood and Cord Tissue Banking
The history of cord blood and tissue banking dates back to the early 1990’s when three private cord blood banks were formed within the United States. These banks were Cord Blood Registry, Cryo-Cell, and Viacord, all of which are AABB accredited banks. Shortly thereafter, cord blood banks began forming in leading healthcare markets worldwide.
In this article:
Gaia Biomedicine & TreeFrog Therapeutics announce collaboration for the expansion of allogeneic NK-like cells against solid tumors
FUKUOKA, Japan, and BORDEAUX, France / February 15th, 2023 – GAIA BioMedicine, a Japan-based clinical-stage company pioneering allogeneic NK-like cell therapies against solid tumors, and TreeFrog Therapeutics, a global biotechnology company advancing a pipeline of cell therapies based on the biomimetic C-Stem™ technology platform, today announced they have entered into a collaboration for the expansion of donor-derived NK-like cells. [Read more…]
FDA Grants RMAT Designation for Rexlemestrocel-L in Chronic Low Back Pain
NEW YORK, Feb. 08, 2023 — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that the United States Food and Drug Administration’s (FDA) Office of Tissues and Advanced Therapies (OTAT) has granted Regenerative Medicine Advanced Therapy (RMAT) designation for rexlemestrocel-L in the treatment of chronic low back pain (CLBP) associated with disc degeneration, in combination with hyaluronic acid (HA) as delivery agent for injection into the lumbar disc. [Read more…]
Immunotherapy company iPSirius appoints Dr. Stephen Sullivan as Chief Operating Officer
iPSirius appoints COO to oversee human trials with allogeneic cancer vaccines made from stem cells
Paris, France, 10th February 2023 – iPSirius, a pre-clinical biotech company in the immuno-oncology field, is pleased to announce the appointment of a new COO, Dr. Stephen Sullivan. Dr. Sullivan, previously the program manager at the Global Alliance for iPSC therapies, is a pluripotent stem cell manufacturing expert. He will oversee the day-to-day operations of the company and the first in-human trials for the company’snovel therapeutic, IPVAC. [Read more…]
- « Previous Page
- 1
- …
- 131
- 132
- 133
- 134
- 135
- …
- 338
- Next Page »